Page 7 - Pacific Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ADVERTISEMENT ADVERTISEMENT Fed. Circ. Probes Alleged Misconduct In DNA Tech IP Fight Law360 (April 6, 2021, 6:41 PM EDT) -- A Federal Circuit judge focused the bulk of his questions Tuesday on allegations that Oxford Nanopore Technologies Ltd. used fearmongering over the COVID-19 pandemic to influence the jury to its advantage in Pacific Biosciences' suit over its DNA analysis patents. A three-judge panel was considering Pacific Biosciences of California Inc.'s appeal of a Delaware federal jury's determination that two of its patents are invalid for lack of enablement, thereby clearing Oxfo...

Share this article Share this article ResearchAndMarkets.com's offering. The publisher predicts that the global market for digital genome would witness a CAGR of 9.57% over the forecast period 2021-2028. It garnered $10061.6 million in 2020, and is estimated to generate net revenue of approximately $20902.1 million by 2028. In recent years, the incidence of chronic diseases has amplified, in turn creating a huge burden on the healthcare system. This has majorly created the demand for the adoption of the digital genome technology. Further, support by the government in the form of funds for de...

SoftBank to invest $900m in US gene sequencing firm Pacific Biosciences Genetics is a key element of healthcare puzzles. February 11, 2021 Pacific Biosciences of California Inc said on Wednesday SoftBank Group Corp will invest $900 million in the gene-sequencing firm, sending its shares up 21% before the bell. The latest healthcare investment from SoftBank, in the form of convertible debt, will help accelerate the commercialization of Pacific Biosciences’ gene sequencing technology. Last month, Bloomberg News reported that SoftBank had picked up a 6% stake in the company. Pacific Bios...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Pacific Biosciences of California, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial ... Pacific Biosciences of California, Inc.February 10, 2021 GMT MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2020. Reported revenue is consistent with the Company’s press release issued on January 11, 2021. Q4 2020 Financial Highlights Revenue for the fo...

Shares of Pacific Biosciences of California traded to a new 52-week high after the firm reported that a Softbank Group subsidiary will invest $900 million to support its growth initiatives.